Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,052
archived clinical trials in
Nephrology

Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
839
mi
from
Royal Oak, MI
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
839
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1263
mi
from
New Brunswick, NJ
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1263
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1056
mi
from
Buffalo, NY
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1056
mi
from
Buffalo, NY
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1296
mi
from
Flushing, NY
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1296
mi
from
Flushing, NY
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1051
mi
from
Durham, NC
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1051
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
895
mi
from
Cleveland, OH
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
895
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1053
mi
from
Charlottesville, VA
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1053
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1117
mi
from
Tampa, FL
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1117
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
959
mi
from
Charlotte, NC
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
959
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1225
mi
from
Philadelphia, PA
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
971
mi
from
Pittsburgh, PA
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
971
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
5602
mi
from
Ciudad Autonoma de Buenos Aires,
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
5602
mi
from
Ciudad Autonoma de Buenos Aires,
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1291
mi
from
Bronx, NY
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1291
mi
from
Bronx, NY
Click here to add this to my saved trials
Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
An Open-Label Phase I/II Pilot Study to Assess the Safety/Tolerability and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
An Open-Label Phase I/II Pilot Study to Assess the Safety/Tolerability and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
Evaluation of Ureteral Stents in the Management of Stone Disease
Evaluation of Ureteral Stents in the Management of Stone Disease
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Evaluation of Ureteral Stents in the Management of Stone Disease
Evaluation of Ureteral Stents in the Management of Stone Disease
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1143
mi
from
San Diego, CA
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1143
mi
from
San Diego, CA
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
610
mi
from
Chicago, IL
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
610
mi
from
Chicago, IL
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
552
mi
from
Minneapolis, MN
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
418
mi
from
Saint Louis, MO
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
418
mi
from
Saint Louis, MO
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
895
mi
from
Cleveland, OH
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
895
mi
from
Cleveland, OH
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
332
mi
from
Plano, TX
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
332
mi
from
Plano, TX
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
779
mi
from
Salt Lake City, UT
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
779
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated:  12/31/1969
Research Site
8593
mi
from
New Lambton,
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Research Site
8593
mi
from
New Lambton,
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
676
mi
from
Birmingham, AL
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
676
mi
from
Birmingham, AL
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
1341
mi
from
San Francisco, CA
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
1341
mi
from
San Francisco, CA
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Emory University School of Medicine
803
mi
from
Atlanta, GA
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Emory University School of Medicine
803
mi
from
Atlanta, GA
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Feinstein Institute, North Shore Hospital
1290
mi
from
Manhasset, NY
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Feinstein Institute, North Shore Hospital
1290
mi
from
Manhasset, NY
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
New York University Langone Medical Center
1288
mi
from
New York, NY
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
New York University Langone Medical Center
1288
mi
from
New York, NY
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Medical College: Hospital for Special Surgery -
1289
mi
from
New York, NY
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Medical College: Hospital for Special Surgery -
1289
mi
from
New York, NY
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
1286
mi
from
New York, NY
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
1286
mi
from
New York, NY
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
University of North Carolina School of Medicine
1044
mi
from
Chapel Hill, NC
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
University of North Carolina School of Medicine
1044
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
The Ohio State University, Wexner Medical Center
810
mi
from
Columbus, OH
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
The Ohio State University, Wexner Medical Center
810
mi
from
Columbus, OH
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
1063
mi
from
Charleston, SC
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
1063
mi
from
Charleston, SC
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern
345
mi
from
Dallas, TX
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern
345
mi
from
Dallas, TX
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
UCLA Medical Center: Division of Rheumatology
1168
mi
from
Los Angeles, CA
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
UCLA Medical Center: Division of Rheumatology
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver: School of Medicine: Division of Rheumatology
mi
from
Aurora, CO
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver: School of Medicine: Division of Rheumatology
mi
from
Aurora, CO
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Colorado Kidney Care
408
mi
from
Denver, CO
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Colorado Kidney Care
408
mi
from
Denver, CO
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis
413
mi
from
Saint Louis, MO
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis
413
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy
Status: Enrolling
Updated:  12/31/1969
University of Alabama
683
mi
from
Birmingham, AL
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy
Status: Enrolling
Updated: 12/31/1969
University of Alabama
683
mi
from
Birmingham, AL
Click here to add this to my saved trials
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
515
mi
from
Rochester, MN
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
515
mi
from
Rochester, MN
Click here to add this to my saved trials
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy
Status: Enrolling
Updated:  12/31/1969
University of Mississippi
571
mi
from
Jackson, MS
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy
Status: Enrolling
Updated: 12/31/1969
University of Mississippi
571
mi
from
Jackson, MS
Click here to add this to my saved trials
Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Status: Enrolling
Updated:  12/31/1969
Stanford University
1329
mi
from
Palo Alto, CA
Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Status: Enrolling
Updated: 12/31/1969
Stanford University
1329
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Jacksonville
1061
mi
from
Jacksonville, FL
Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Jacksonville
1061
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
515
mi
from
Rochester, MN
Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
515
mi
from
Rochester, MN
Click here to add this to my saved trials
Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
1286
mi
from
New York, NY
Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
1286
mi
from
New York, NY
Click here to add this to my saved trials
Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome
Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome (RAMP)
Status: Enrolling
Updated:  12/31/1969
Nationwide Children's Hospital
811
mi
from
Columbus, OH
Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome
Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome (RAMP)
Status: Enrolling
Updated: 12/31/1969
Nationwide Children's Hospital
811
mi
from
Columbus, OH
Click here to add this to my saved trials
TCUPS- Tolvaptan Use in Cyctinuria and Urolithiasis: A Pilot Study
Use of Tolvaptan, a Vasopressin Antagonist, to Increase Urine Dilution and Reduce Cystine Urolithiasis Among Patients With Homozygous Cystinuria: a Pilot Investigation
Status: Enrolling
Updated:  12/31/1969
Boston Children's Hospital
1444
mi
from
Boston, MA
TCUPS- Tolvaptan Use in Cyctinuria and Urolithiasis: A Pilot Study
Use of Tolvaptan, a Vasopressin Antagonist, to Increase Urine Dilution and Reduce Cystine Urolithiasis Among Patients With Homozygous Cystinuria: a Pilot Investigation
Status: Enrolling
Updated: 12/31/1969
Boston Children's Hospital
1444
mi
from
Boston, MA
Click here to add this to my saved trials